Tocqueville Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Tocqueville Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-40,000	Closed	-$168K	–	556
2023 Q1	$168K	Buy	40,000 +26,000	+186%	+$135K	﹤0.01%	508
2022 Q4	$84.1K	Buy	+14,000	New	+$76.4K	﹤0.01%	565

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Tocqueville Asset Management's CTIC Position: Q2 2023 in Review

Tocqueville Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 40,000 shares — an estimated $168K sold.

Tocqueville Asset Management first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $168K in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Tocqueville Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Tocqueville Asset Management sold 40,000 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $168K.
Tocqueville Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
Tocqueville Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $168K in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Tocqueville Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.